LEUKEMIA 360: A Unique Event to Accelerate Research on Leukemia and Related Diseases on November 13 in Paris
Press Release – November 1, 2024
Paris, October 30, 2024 – The countdown has begun! In less than two weeks, the inaugural edition of LEUKEMIA 360 will open in Paris, bringing together over 200 experts in leukemia and related diseases.
With participation from pharmaceutical, biotech, and diagnostics industries, academic laboratories and groups, as well as other key ecosystem stakeholders (investors, patient associations, institutions, consultants), and world-renowned speakers including Professors Marina Konopleva (Montefiore Einstein Cancer Center), Yang Shen (Shanghai Institute of Hematology), Richard Stone (Dana-Farber Institute), Hugues de Thé (THEMA Saint-Louis Institute), Sylvie Freeman (University of Birmingham), and Robert Zeiser (University of Freiburg), LEUKEMIA 360 aims to establish itself as the premier event for partnership-based research on leukemia.
A Strategic Gathering for Innovators and Developers of Therapeutics and Diagnostic Solutions
Organized by Institut Carnot OPALE and endorsed by the French National Cancer Institute (INCa), LEUKEMIA 360 seeks to foster partnerships between academia and industry to accelerate therapeutic and diagnostic innovation. Professor Norbert Ifrah, President of INCa, and Stéphanie Fugain, President of the Laurette Fugain patient association, will also speak at the event, underscoring the significance of institutional synergies and patient involvement in research. Together, they will highlight the urgency of tackling leukemia and related blood cancers, the deadliest blood malignancies and the leading cancers affecting children and adolescents.
LEUKEMIA 360 Objectives: Driving Collaborations to Accelerate Market Access for Leukemia Innovations
For the first time, LEUKEMIA 360 will bring together more than 40 leading academic entities specializing in leukemia, showcasing an unmatched panel of innovations, scientific offerings, and research and development (R&D) capabilities on an international scale. The event aims to spotlight the French network of excellence, its global collaborations, and its impressive results—including OPALE’s collaboration with over 170 socio-economic partners and over 580 R&D projects conducted within four years under the Carnot label. LEUKEMIA360 also seeks to attract new industrial partners eager to invest in this dynamic field.
“With LEUKEMIA 360, we aim to leverage France’s exceptional oncology ecosystem and provide industry players with the expertise and tools needed to capitalize on their and our innovations in leukemia and related diseases, collectively addressing the field’s significant unmet medical needs more efficiently,” says Professor Hervé Dombret, President of Institut Carnot OPALE.
Why Attend LEUKEMIA 360?
- Expertise and Networking: Meet international opinion leaders and top experts in leukemia and related diseases to discuss the field's challenges.
- Satellite Workshops and 1:1 Meetings: Engage in interactive sessions with academic researchers and clinicians, exploring their R&D offerings.
- Partnership Opportunities: Discover resources to fast-track your R&D projects and explore innovative collaboration models.
Practical Information
- Date: November 13, 2024
- Venue: Ministry of the Economy and Finance, 139 Rue de Bercy, Paris 12th
- Registration: Mandatory; spots are limited, with final registration closing on November 5.
- Website: www.leukemia360.org
About Institut Carnot OPALE
Labeled Carnot in 2020, Institut Carnot OPALE is dedicated exclusively to partnership-based research in leukemia and related diseases. Leveraging cutting-edge research and expertise, OPALE accelerates therapeutic and diagnostic innovation across the entire R&D value chain—from fundamental research to real-world monitoring. It encompasses target discovery, preclinical, translational, and clinical research (including CAR-T bioproduction for clinical trials), and provides access to comprehensive biological collections and databases.
With around 500 researchers, clinicians, and operational staff across 27 entities led by scientific opinion leaders, supported by top institutions (INSERM, CNRS, CEA, EFS, AP-HP, Université Paris Cité, etc.), and engaged in numerous international collaborations, OPALE offers industrial partners a unique and professionalized access to unmatched resources and expertise in this field. OPALE also supports entrepreneurship through licensing, spinoffs, and academic partnerships (PSCC, OncoSTART, BioLaunchpad).